Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

UroGen Pharma (URGN) EPS (Basic) (2016 - 2025)

Historic EPS (Basic) for UroGen Pharma (URGN) over the last 10 years, with Q3 2025 value amounting to -$0.69.

  • UroGen Pharma's EPS (Basic) fell 3529.41% to -$0.69 in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.46, marking a year-over-year decrease of 1849.32%. This contributed to the annual value of -$2.7 for FY2024, which is 2400.91% up from last year.
  • As of Q3 2025, UroGen Pharma's EPS (Basic) stood at -$0.69, which was down 3529.41% from -$1.05 recorded in Q2 2025.
  • Over the past 5 years, UroGen Pharma's EPS (Basic) peaked at -$0.51 during Q3 2024, and registered a low of -$1.35 during Q3 2021.
  • For the 5-year period, UroGen Pharma's EPS (Basic) averaged around -$1.01, with its median value being -$1.05 (2025).
  • As far as peak fluctuations go, UroGen Pharma's EPS (Basic) skyrocketed by 4240.0% in 2023, and later crashed by 3529.41% in 2025.
  • Quarter analysis of 5 years shows UroGen Pharma's EPS (Basic) stood at -$1.27 in 2021, then rose by 1.57% to -$1.25 in 2022, then soared by 42.4% to -$0.72 in 2023, then decreased by 10.78% to -$0.8 in 2024, then grew by 13.49% to -$0.69 in 2025.
  • Its last three reported values are -$0.69 in Q3 2025, -$1.05 for Q2 2025, and -$0.92 during Q1 2025.